APA
Apellániz-Ruiz M., Inglada-Pérez L., Naranjo M. E. G., Sánchez L., Mancikova V., Currás-Freixes M., de Cubas A. A., Comino-Méndez I., Triki S., Rebai A., Rasool M., Moya G., Grazina M., Opocher G., Cascón A., Taboada-Echalar P., Ingelman-Sundberg M., Carracedo A., Robledo M., Llerena A. & Rodríguez-Antona C. (20160210). High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme. : The pharmacogenomics journal.
Chicago
Apellániz-Ruiz M, Inglada-Pérez L, Naranjo M E G, Sánchez L, Mancikova V, Currás-Freixes M, de Cubas A A, Comino-Méndez I, Triki S, Rebai A, Rasool M, Moya G, Grazina M, Opocher G, Cascón A, Taboada-Echalar P, Ingelman-Sundberg M, Carracedo A, Robledo M, Llerena A and Rodríguez-Antona C. 20160210. High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme. : The pharmacogenomics journal.
Harvard
Apellániz-Ruiz M., Inglada-Pérez L., Naranjo M. E. G., Sánchez L., Mancikova V., Currás-Freixes M., de Cubas A. A., Comino-Méndez I., Triki S., Rebai A., Rasool M., Moya G., Grazina M., Opocher G., Cascón A., Taboada-Echalar P., Ingelman-Sundberg M., Carracedo A., Robledo M., Llerena A. and Rodríguez-Antona C. (20160210). High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme. : The pharmacogenomics journal.
MLA
Apellániz-Ruiz M, Inglada-Pérez L, Naranjo M E G, Sánchez L, Mancikova V, Currás-Freixes M, de Cubas A A, Comino-Méndez I, Triki S, Rebai A, Rasool M, Moya G, Grazina M, Opocher G, Cascón A, Taboada-Echalar P, Ingelman-Sundberg M, Carracedo A, Robledo M, Llerena A and Rodríguez-Antona C. High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme. : The pharmacogenomics journal. 20160210.